

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
MHRA APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL
OF OT-101 IN THE UNITED KINGDOM

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that OT-101 (0.01% atropine sulfate eye drop), a self-developed new drug to treat the progression of myopia in children, was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom to conduct a phase III randomized, double-masked, placebo-controlled, parallel-group, multi-center study on the safety and efficacy in treating the progression of myopia in pediatric subjects.

The phase III clinical trial of OT-101 is the world’s first multi-regional phase III clinical trial for low-concentration atropine and its analogs that includes Chinese population. In April 2021, the first patient enrollment for OT-101’s phase III clinical trial in the United States was completed. In July 2021, OT-101 was also approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the People’s Republic of China to conduct a phase III clinical trial. To date, no low-concentration atropine ophthalmic preparations has been commercialized in the global mainstream pharmaceutical market.

OT-101 (atropine 0.01%) is a low-concentration (0.01%) atropine eye drop developed to retard, or slow down, the progression of myopia in children and adolescents, which is the only anticholinergic medication to date that has been demonstrated to be consistently effective and safe in controlling myopic progression. However, the instability of low-concentration atropine solutions has long been a technical barrier towards commercialization. In response to these obstacles, OT-101 uses an innovative closed-loop split device of exclusive design to improve the reliability, closure integrity and sterility conditions of the device, so that it can be as close as possible to the current medication environment for the preparations of low-concentration atropine for use in the hospital, thus solving the stability problem of low-concentration atropine solution in neutral environment. Also, the appropriate pH value improves the comfort of patients being treated and medication compliance. The Group believes that the technical breakthroughs in response to the stability issue of low-concentration (0.01%) atropine will be its core competitiveness.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize OT-101 (0.01% atropine sulfate eye drop) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, August 2, 2021

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive directors.